COMPUTATIONAL OPTIMISATION OF TARGETED DNA SEQUENCING FOR CANCER DETECTION

Similar documents
Supplementary Materials for

BWA alignment to reference transcriptome and genome. Convert transcriptome mappings back to genome space

underlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The

Supplementary Tables. Supplementary Figures

Supplementary Figure 1. Estimation of tumour content

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser

Supplementary Figure 1: Features of IGLL5 Mutations in CLL: a) Representative IGV screenshot of first

Nature Getetics: doi: /ng.3471

SUPPLEMENTARY INFORMATION

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA

Supplementary Figure 1: Classification scheme for non-synonymous and nonsense germline MC1R variants. The common variants with previously established

The 100,000 Genomes Project Harnessing the power of genomics for NHS rare disease and cancer patients

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer

Discovery Dataset. PD Liver Luminal B/ Her-2+ Letrozole. PD Supraclavicular Lymph node. PD Supraclavicular Lymph node Luminal B.

Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies

Variant Classification. Author: Mike Thiesen, Golden Helix, Inc.

Nature Genetics: doi: /ng Supplementary Figure 1

Enterprise Interest Thermo Fisher Scientific / Employee

Breast cancer. Risk factors you cannot change include: Treatment Plan Selection. Inferring Transcriptional Module from Breast Cancer Profile Data

User s Manual Version 1.0

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

SUPPLEMENTARY APPENDIX

The Role of Genetics in Ovarian Cancer Screening. Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno

Genomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France

Supplementary Figure 1. Metabolic landscape of cancer discovery pipeline. RNAseq raw counts data of cancer and healthy tissue samples were downloaded

SUPPLEMENTARY FIGURES: Supplementary Figure 1

AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB

Epidemiology in Texas 2006 Annual Report. Cancer

Genome. Institute. GenomeVIP: A Genomics Analysis Pipeline for Cloud Computing with Germline and Somatic Calling on Amazon s Cloud. R. Jay Mashl.

Nature Genetics: doi: /ng Supplementary Figure 1. SEER data for male and female cancer incidence from

Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival -- Evidence from TCGA Pan-Cancer Data

Correlation of gene expression and associated mutation profiles of APOBEC3A, chemosensitivity of cancer cell lines to drug treatment

CANCER GENETICS PROVIDER SURVEY

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute

Introduction. Introduction

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

BRCAplus. genetic testing for hereditary breast cancer

Cancer Alliance Data Pack

Mouse Clec9a ORF sequence

Expert-guided Visual Exploration (EVE) for patient stratification. Hamid Bolouri, Lue-Ping Zhao, Eric C. Holland

Towards a Universal Law Controlling All Human Cancer Chromosome LOH Deletions, Perspectives in Prostate and Breast Cancers Screening

SVIM: Structural variant identification with long reads DAVID HELLER MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS, BERLIN JUNE 2O18, SMRT LEIDEN

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center

Nature Medicine: doi: /nm.4439

Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015

Gene-microRNA network module analysis for ovarian cancer

NGS in tissue and liquid biopsy

Clustered mutations of oncogenes and tumor suppressors.

ARTICLE RESEARCH. Macmillan Publishers Limited. All rights reserved

Identification of Tissue Independent Cancer Driver Genes

Trends and disparities in cancer in Aotearoa/ NZ

Cancer genetics

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley

Large-scale identity-by-descent mapping discovers rare haplotypes of large effect. Suyash Shringarpure 23andMe, Inc. ASHG 2017

ciap using fragment based drug discovery

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser

patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

PSSV User Manual (V1.0)

Journal: Nature Methods

OBESITY AND CANCER RISK

OBESITY AND CANCER RISK

6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels

NGS ONCOPANELS: FDA S PERSPECTIVE

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Appendix 1 (as supplied by the authors): Supplementary data

List of Available TMAs in the PRN

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER

Information for You and Your Family

GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Shawnia Ryan, MS, LCGC Senior Genetic Counselor University of New Mexico Cancer Center

Integration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium

Figure 1.1 PHITS geometry for PTB irradiations with: broad beam, upper panel; mono energetic beams, lower panel. Pictures of the setups and of the

Nature Biotechnology: doi: /nbt.1904

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

Molecular Imaging and Cancer

NGS IN ONCOLOGY: FDA S PERSPECTIVE

patient guide MelanomaNext genetic testing for hereditary melanoma Because knowing your risk can mean early detection and prevention

Performance Characteristics BRCA MASTR Plus Dx

Supplementary Online Content

De Novo Viral Quasispecies Assembly using Overlap Graphs

Phase-specific Costs of Cancer Care in Ontario

Supplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the

David Tamborero, PhD

Health Systems Adoption of Personalized Medicine: Promise and Obstacles. Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA

Nature Genetics: doi: /ng Supplementary Figure 1. Rates of different mutation types in CRC.

Nature Medicine: doi: /nm.3967

Foreign antigens in human cancers

Result Navigator. Positive Test Result: PTEN. After a positive test result, there can be many questions about what to do next. Navigate Your Results

iplex genotyping IDH1 and IDH2 assays utilized the following primer sets (forward and reverse primers along with extension primers).

Plasma-Based Molecular Testing for Early Detection of Lung Cancer

A Versatile Algorithm for Finding Patterns in Large Cancer Cell Line Data Sets

Tableau user guide for all Official Statistics

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT OGEN (AN ESTROGEN HORMONE)?

Genetic alterations of histone lysine methyltransferases and their significance in breast cancer

Supplementary Figures

Cancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer

SUPPLEMENTARY INFORMATION

Transcription:

COMPUTATIONAL OPTIMISATION OF TARGETED DNA SEQUENCING FOR CANCER DETECTION Pierre Martinez, Nicholas McGranahan, Nicolai Juul Birkbak, Marco Gerlinger, Charles Swanton* SUPPLEMENTARY INFORMATION SUPPLEMENTARY FIGURE LEGENDS Supplementary Figure 1: Illustration of the hotspot region definition process. For different distance thresholds d, mutations were iteratively grouped into clusters that determined hotspot regions. In the example, the blue and yellow mutations are 13 base pairs apart and there is no reported mutation between them. Using at threshold d=1, these mutations are thus in two different hot spot regions. Increasing d to 2, all 4 mutations will be clustered together in a single hotspot region. Even if the green and red mutations are 21 base pairs apart, all 4 mutations are within 2 base pairs of at least one other mutation in the hotspot region. Any mutation less than 2 base pairs upstream of the red mutation or downstream of the green mutation would be included in the hotspot region. Supplementary Figure2: Computationally estimated sensitivity of targeted sequencing screen for the detection of specific tumor types using specific candidate genes. Left panels: percentage of tumors for each tumor type in each cohort that have at least one mutation in a gene included in panels defined by combining the best 1 to 25 specific candidate genes. Right panels: percentage of tumors for each tumor type that have at least one mutation in a gene included in the best panel of specific genes defined for a maximum length varying from to, nucleotides. Supplementary Figure 3: Proportion of in-frame mutations that are detectable and not detectable by hotspot region targeting approaches in each cohort. Each panel represents a different distance threshold d used to define the hotspot regions. P- values are given by two-tailed Fisher s exact tests. Supplementary Figure 4: Computationally estimated sensitivity of targeted SNV sequencing screen for the detection of specific tumour types using pan-cancer candidate SNVs. Percentage of tumours for each tumour type in each cohort that have at least one mutation in panels defined by iteratively combining the best 1, pan-cancer single nucleotide variants.

Martinez et al. Supplementary Figure 1 hotspot regions d=2 hotspot regions d=1 mutations DNA sequence * * * * d = 5 d = 13 d = 3

Martinez et al. Supplementary Figure 2 Discovery (TCGA early) Breast Head & Neck Lung Ade. Ovarian Thyroid Colorectal Kidney clear cell Lung Sq. Melanoma Uterus 5 1 15 2 25 1 2 3 4 5 Validation (TCGA late) 5 1 15 2 25 1 2 3 4 5 Validation (non TCGA) 5 1 15 2 25 Gene panel length (number of genes) 1 2 3 4 5 Gene panel length (kbp)

Martinez et al. Supplementary Figure 3 4 2 dist = 1bp p=1.46e 89 p=.882 p=1.33e 35 4 2 dist = 2bp p=1.85e 59 p=.13 p=4.96e 61 4 2 dist = 5bp p=1.99e 28 p=3.7e 5 p=1.6e 89 4 2 dist = bp p=6.19e 16 p=8.22e 11 p=1.19e 15 4 2 dist = 2bp p=2.69e 12 p=6.77e 12 p=4.98e 119 4 2 dist = 5bp p=2.17e 7 p=8.85e 15 p=3.48e 129 Discovery (TCGA early) Validation (TCGA late) Validation (non TCGA)

Martinez et al. Supplementary Figure 4 Discovery (TCGA early) 2 4 Validation (TCGA late) 2 4 Validation (non TCGA) 2 4 Number of single nucleotide substitutions Breast Colorectal Head & Neck Kidney clear cell Lung Ade. Lung Sq. Ovarian Melanoma Thyroid Uterus